- List
- By Topic
- On Map
- Search Details

shingles (408 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT02704572 | Completed | Optimal Timing of Zoster Vaccine After Zoster Illness |
|
|
Interventional | Not Applicable |
|
Other |
|
|
60 | All | 50 Years and older (Adult, Senior) | NCT02704572 | H1511046718 | March 2016 | August 2017 | August 2017 | March 10, 2016 | October 13, 2017 |
|
||
2 | NCT01331161 | Completed Has Results |
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly |
|
|
Interventional | Not Applicable |
|
Other / NIH |
|
|
77 | All | 25 Years to 79 Years (Adult, Senior) | NCT01331161 | IRB00050285 U19AI090023 HIPCVAX005 |
July 2011 | April 2012 | October 2012 | April 7, 2011 | February 17, 2016 | February 17, 2016 |
|
|
3 | NCT02624375 | Recruiting | Immune Response to Shingles Vaccination |
|
|
Interventional | Phase 4 |
|
Other / Industry |
|
|
50 | All | 70 Years and older (Senior) | NCT02624375 | STUDY00001399 53354 |
February 2016 | December 2018 | December 2018 | December 8, 2015 | April 3, 2018 |
|
||
4 | NCT01519570 | Completed | Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates |
|
|
Interventional | Not Applicable |
|
Other |
|
|
2589 | All | 60 Years and older (Adult, Senior) | NCT01519570 | 2010H0290 | March 2011 | December 2011 | December 2011 | January 27, 2012 | January 27, 2012 |
|
||
5 | NCT03314103 | Recruiting | Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age |
|
|
Interventional | Phase 3 |
|
Other |
|
|
30000 | All | 40 Years and older (Adult, Senior) | NCT03314103 | CS-HZ-2017 | October 6, 2017 | October 30, 2019 | December 30, 2019 | October 19, 2017 | October 19, 2017 |
|
||
6 | NCT03016884 | Recruiting | Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients |
|
|
Interventional | Phase 4 |
|
Other |
|
|
250 | All | 50 Years and older (Adult, Senior) | NCT03016884 | 142-016-EMC | January 2017 | January 2019 | May 2019 | January 11, 2017 | January 30, 2018 |
|
||
7 | NCT02735915 | Active, not recruiting | Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
70 | All | 68 Years and older (Senior) | NCT02735915 | 204926 2015-004400-30 |
April 11, 2016 | August 28, 2017 | November 28, 2018 | April 13, 2016 | April 17, 2018 |
|
||
8 | NCT02690207 | Active, not recruiting | Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies. |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
14535 | All | 50 Years and older (Adult, Senior) | NCT02690207 | 204486 2015-000965-30 |
March 16, 2016 | May 24, 2019 | May 24, 2019 | February 24, 2016 | April 24, 2018 |
|
||
9 | NCT02723773 | Active, not recruiting | A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
7732 | All | 50 Years and older (Adult, Senior) | NCT02723773 | 201190 2015-001778-17 |
April 16, 2016 | July 28, 2023 | July 28, 2023 | March 30, 2016 | March 13, 2018 |
|
||
10 | NCT01911065 | Completed Has Results |
T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020 |
|
|
Interventional | Phase 4 |
|
Other / NIH |
|
|
54 | All | 40 Years and older (Adult, Senior) | NCT01911065 | SU-19385 1U19AI090019-01 |
September 2010 | December 2011 | December 2011 | July 30, 2013 | April 21, 2017 | March 3, 2017 |
|
|
11 | NCT01165177 | Completed Has Results |
Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
16165 | All | 50 Years and older (Adult, Senior) | NCT01165177 | 110390 2008-000367-42 |
August 1, 2010 | May 9, 2014 | July 27, 2015 | July 19, 2010 | March 14, 2018 | May 1, 2017 |
|
|
12 | NCT01245751 | Completed Has Results |
Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029) |
|
|
Interventional | Phase 3 |
|
Industry / Other |
|
|
600 | All | 50 Years and older (Adult, Senior) | NCT01245751 | V211-029 | April 2011 | July 2012 | May 2015 | November 22, 2010 | April 12, 2017 | May 29, 2013 | ||
13 | NCT01165229 | Completed Has Results |
Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
14819 | All | 70 Years and older (Senior) | NCT01165229 | 113077 2009-015791-94 |
August 2, 2010 | July 24, 2015 | July 24, 2015 | July 19, 2010 | February 1, 2018 | November 20, 2017 |
|
|
14 | NCT02514018 | Active, not recruiting | Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus Vaccine |
|
|
Interventional | Phase 4 |
|
Other |
|
|
45 | Female | 18 Years to 50 Years (Adult) | NCT02514018 | KAVI-VZV-001 | KAVI-VZV-001 | September 2015 | January 2017 | July 2017 | August 3, 2015 | October 17, 2016 |
|
|
15 | NCT01600079 | Active, not recruiting | ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024) |
|
|
Observational |
|
Industry / Other |
|
|
30000 | All | 50 Years and older (Adult, Senior) | NCT01600079 | V211-024 8003.016 |
May 15, 2012 | October 30, 2023 | October 30, 2023 | May 16, 2012 | October 20, 2017 | ||||
16 | NCT00007501 | Completed | Shingles Prevention Study |
|
|
Interventional | Phase 3 |
|
U.S. Fed / Industry / NIH |
|
|
38456 | All | 60 Years and older (Adult, Senior) | NCT00007501 | 403 | SPS | November 1998 | April 2004 | February 2011 | January 1, 2001 | July 4, 2013 |
|
|
17 | NCT02114333 | Active, not recruiting | Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
160 | All | 50 Years to 85 Years (Adult, Senior) | NCT02114333 | 13-3192 | May 2014 | March 2016 | December 2019 | April 15, 2014 | March 3, 2017 |
|
||
18 | NCT02408159 | Terminated | Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy |
|
|
Interventional | Phase 4 |
|
Other / Industry |
|
|
3 | All | 50 Years and older (Adult, Senior) | NCT02408159 | Inno-6041 | June 2016 | January 2017 | March 2017 | April 3, 2015 | July 2, 2017 |
|
||
19 | NCT03192319 | Recruiting | Optimal Timing of Zoster Vaccine After Hematopoietic Stem Cell Transplantation |
|
|
Interventional | Not Applicable |
|
Other |
|
|
120 | All | 50 Years and older (Adult, Senior) | NCT03192319 | H1705030852 | July 1, 2017 | May 31, 2018 | May 31, 2018 | June 20, 2017 | November 14, 2017 |
|
||
20 | NCT01262300 | Active, not recruiting | Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents |
|
|
Interventional | Phase 1 |
|
Other / NIH / Industry |
|
|
33 | All | 60 Years and older (Adult, Senior) | NCT01262300 | 10-0189 K23AG040708 |
November 2010 | November 2014 | December 2018 | December 17, 2010 | December 2, 2017 |
|
||
21 | NCT00900783 | Completed | A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
350 | All | 50 Years and older (Adult, Senior) | NCT00900783 | INH-FV1-005 INH-FV1-005-PK INH-FV1-005-VR INH-FV1-AGE |
May 2009 | November 2010 | December 2010 | May 13, 2009 | October 12, 2015 | |||
22 | NCT00109122 | Completed | Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007) |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
180 | All | 60 Years and older (Adult, Senior) | NCT00109122 | V211-007 2005_017 |
November 2001 | February 2003 | July 2006 | April 25, 2005 | March 15, 2017 | |||
23 | NCT02832986 | Completed | Herpes Zoster Prevalence in Frailty Consultations |
|
|
Observational |
|
Other |
|
|
1245 | All | 65 Years and older (Adult, Senior) | NCT02832986 | RC31-15-7581 | January 2015 | December 2015 | June 2016 | July 14, 2016 | July 14, 2016 |
|
|||
24 | NCT00322231 | Completed Has Results |
A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
101 | All | 50 Years and older (Adult, Senior) | NCT00322231 | V211-014 2006_010 |
May 2006 | July 2007 | July 2007 | May 5, 2006 | January 26, 2015 | December 15, 2010 | ||
25 | NCT00130793 | Completed Has Results |
A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
368 | All | 50 Years and older (Adult, Senior) | NCT00130793 | V211-010 2005_035 |
August 2005 | November 2005 | November 2005 | August 16, 2005 | January 26, 2015 | July 3, 2009 | ||
26 | NCT01610414 | Completed Has Results |
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
1877 | All | 18 Years and older (Adult, Senior) | NCT01610414 | 115523 2012-000138-20 |
July 13, 2012 | November 4, 2016 | February 1, 2017 | June 4, 2012 | January 23, 2018 | January 23, 2018 |
|
|
27 | NCT00434577 | Completed | Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
715 | All | 60 Years and older (Adult, Senior) | NCT00434577 | 108494 108516 108518 108520 |
February 2007 | October 2007 | July 2010 | February 13, 2007 | March 28, 2012 |
|
||
28 | NCT03493776 | Recruiting New |
Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation |
|
|
Interventional | Phase 4 |
|
Other |
|
|
75 | All | 50 Years and older (Adult, Senior) | NCT03493776 | UHN-Shingrix-001 | April 15, 2018 | September 5, 2019 | March 5, 2020 | April 10, 2018 | April 10, 2018 |
|
||
29 | NCT01827839 | Completed Has Results |
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
96 | All | 50 Years and older (Adult, Senior) | NCT01827839 | 116796 2012-003643-30 |
June 10, 2013 | February 10, 2014 | November 25, 2014 | April 10, 2013 | November 27, 2017 | March 7, 2017 |
|
|
30 | NCT02075515 | Completed Has Results |
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
651 | All | 50 Years and older (Adult, Senior) | NCT02075515 | 117177 2013-000373-76 |
August 13, 2014 | April 29, 2015 | April 25, 2016 | March 3, 2014 | May 24, 2017 | May 24, 2017 |
|
|
31 | NCT00118885 | Completed | Shingles: Immune Effects of Tai Chi |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
140 | All | 60 Years to 90 Years (Adult, Senior) | NCT00118885 | AG0029 R01AG018367 |
July 2001 | December 2004 | December 2004 | July 12, 2005 | December 11, 2009 |
|
||
32 | NCT01573182 | Recruiting | Herpes Zoster Vaccine for Bone Marrow Transplant Donors |
|
|
Interventional | Phase 2 |
|
Other |
|
|
10 | All | 50 Years and older (Adult, Senior) | NCT01573182 | VADOVAR | VZV-Zostavax | April 2012 | December 2017 | December 2018 | April 6, 2012 | May 4, 2017 |
|
|
33 | NCT00561080 | Completed Has Results |
Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
759 | All | 70 Years and older (Senior) | NCT00561080 | V211-043 X06-Z-305 2007-000744-28 |
October 26, 2007 | June 3, 2009 | June 3, 2009 | November 20, 2007 | February 16, 2018 | December 22, 2017 | ||
34 | NCT02590068 | Terminated | Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination |
|
|
Interventional | Not Applicable |
|
Other / NIH |
|
|
14 | All | 50 Years to 60 Years (Adult) | NCT02590068 | OJE-0890 5U19AI111825-02 |
December 2015 | September 8, 2017 | September 8, 2017 | October 28, 2015 | November 24, 2017 |
|
||
35 | NCT01777321 | Completed Has Results |
Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
60 | All | 50 Years and older (Adult, Senior) | NCT01777321 | 116760 2012-005671-14 |
June 17, 2013 | October 10, 2013 | November 11, 2014 | January 28, 2013 | December 21, 2017 | January 6, 2017 |
|
|
36 | NCT01086449 | Completed | Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
20 | All | 18 Years to 69 Years (Adult, Senior) | NCT01086449 | 113819 | March 4, 2010 | June 25, 2010 | November 25, 2010 | March 15, 2010 | March 9, 2018 |
|
||
37 | NCT00920218 | Completed Has Results |
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
121 | All | 18 Years and older (Adult, Senior) | NCT00920218 | 110258 | July 14, 2009 | April 26, 2011 | March 21, 2012 | June 15, 2009 | December 12, 2017 | December 12, 2017 |
|
|
38 | NCT02979639 | Active, not recruiting | Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
404 | All | 50 Years and older (Adult, Senior) | NCT02979639 | 204928 | January 16, 2017 | April 12, 2017 | August 14, 2018 | December 1, 2016 | March 19, 2018 |
|
||
39 | NCT00534248 | Completed Has Results |
Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
22439 | All | 50 Years to 59 Years (Adult) | NCT00534248 | V211-022 2007_551 |
October 2007 | January 2010 | January 2010 | September 24, 2007 | April 12, 2017 | May 2, 2011 | ||
40 | NCT02679339 | Terminated | Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
1 | All | 18 Years to 85 Years (Adult, Senior) | NCT02679339 | 2022-HZ-011 | January 2015 | August 2015 | August 2015 | February 10, 2016 | February 10, 2016 |
|
||
41 | NCT01527370 | Completed Has Results |
Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
250 | All | 50 Years and older (Adult, Senior) | NCT01527370 | V211-025 CTRI/2012/08/002922 |
October 2012 | April 2013 | April 2013 | February 7, 2012 | April 12, 2017 | December 30, 2013 | ||
42 | NCT03120962 | Not yet recruiting | Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia |
|
|
Interventional | Not Applicable |
|
Other |
|
|
140 | All | 50 Years and older (Adult, Senior) | NCT03120962 | 2017-012 | May 2017 | May 2020 | November 2020 | April 19, 2017 | April 19, 2017 | |||
43 | NCT01556451 | Completed Has Results |
ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034) |
|
|
Interventional | Phase 4 |
|
Industry |
|
|
180 | All | 50 Years and older (Adult, Senior) | NCT01556451 | V211-034 | April 2012 | October 2012 | October 2012 | March 16, 2012 | April 12, 2017 | September 23, 2013 | ||
44 | NCT01254630 | Completed Has Results |
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
5305 | All | 18 Years and older (Adult, Senior) | NCT01254630 | V212-011 CTRI/2012/05/002673 2010-023156-89 |
June 24, 2011 | April 11, 2017 | April 11, 2017 | December 6, 2010 | April 13, 2018 | April 13, 2018 | ||
45 | NCT00487682 | Completed | Dose-finding Study of ASP2151 in Subjects With Herpes Zoster |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
403 | All | 20 Years to 79 Years (Adult, Senior) | NCT00487682 | 15L-CL-221 | August 2007 | September 2008 | September 2008 | June 18, 2007 | December 21, 2011 |
|
||
46 | NCT01165203 | Completed Has Results |
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
123 | All | 18 Years and older (Adult, Senior) | NCT01165203 | 112673 | September 30, 2010 | July 6, 2012 | May 14, 2013 | July 19, 2010 | November 27, 2017 | June 7, 2017 |
|
|
47 | NCT01229267 | Completed | A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (Study No. V212-001 AM4) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
1257 | All | 18 Years and older (Adult, Senior) | NCT01229267 | V212-001 | November 2010 | December 2015 | December 2015 | October 27, 2010 | July 28, 2016 | |||
48 | NCT01798056 | Completed | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
237 | All | 18 Years and older (Adult, Senior) | NCT01798056 | 116427 2012-002966-11 |
March 2013 | June 2015 | May 2016 | February 25, 2013 | October 6, 2016 |
|
||
49 | NCT00886613 | Completed Has Results |
A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003) |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
120 | All | 60 Years and older (Adult, Senior) | NCT00886613 | V212-003 2009_579 |
March 2009 | December 2009 | December 2009 | April 23, 2009 | October 6, 2015 | April 13, 2011 | ||
50 | NCT01483378 | Completed Has Results |
Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital |
|
|
Interventional | Not Applicable |
|
Other / Industry |
|
|
170 | All | 60 Years and older (Adult, Senior) | NCT01483378 | 11-02029 | January 2012 | February 2012 | February 2012 | December 1, 2011 | August 9, 2013 | August 9, 2013 |
|
† Study has passed its completion date and status has not been verified in more than two years.